420 related articles for article (PubMed ID: 7916039)
21. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
Harris RE; Termuhlen AM; Smith LM; Lynch J; Henry MM; Perkins SL; Gross TG; Warkentin P; Vlachos A; Harrison L; Cairo MS
Biol Blood Marrow Transplant; 2011 Feb; 17(2):249-58. PubMed ID: 20637881
[TBL] [Abstract][Full Text] [Related]
22. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant.
Arranz R; Tomás JF; Gil-Fernández JJ; Martínez-Chamorro C; Granados E; Alegre A; Figuera A; Vázquez L; Cámara R; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Apr; 21(8):779-86. PubMed ID: 9603401
[TBL] [Abstract][Full Text] [Related]
23. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Weaver CH; Appelbaum FR; Petersen FB; Clift R; Singer J; Press O; Bensinger W; Bianco J; Martin P; Anasetti C
J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
[TBL] [Abstract][Full Text] [Related]
24. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
25. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
[TBL] [Abstract][Full Text] [Related]
26. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[TBL] [Abstract][Full Text] [Related]
27. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Stuart MJ; Chao NS; Horning SJ; Wong RM; Negrin RS; Johnston LJ; Shizuru JA; Long GD; Blume KG; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2001; 7(10):552-60. PubMed ID: 11760087
[TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
Burns LJ; Daniels KA; McGlave PB; Miller WJ; Ramsay NK; Kersey JH; Weisdorf DJ
Bone Marrow Transplant; 1995 Jul; 16(1):13-8. PubMed ID: 7581112
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Spinolo JA; Jagannath S; Velásquez W; Spitzer G; Cabanillas F; Hagemeister F; Horwitz LJ; Dicke KA
Leuk Lymphoma; 1993 Jan; 9(1-2):71-7. PubMed ID: 8477204
[TBL] [Abstract][Full Text] [Related]
31. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
Patti C; Majolino I; Scimè R; Indovina A; Vasta S; Liberti G; Gentile S; Santoro A; Pisa R; Caronia F
Eur J Haematol; 1993 Jul; 51(1):18-24. PubMed ID: 8348940
[TBL] [Abstract][Full Text] [Related]
32. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
Ozkaynak MF; Matthay K; Cairo M; Harris RE; Feig S; Reynolds CP; Buckley J; Villablanca JG; Seeger RC
J Clin Oncol; 1998 Mar; 16(3):937-44. PubMed ID: 9508176
[TBL] [Abstract][Full Text] [Related]
33. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
34. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
35. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group.
Fleming DR; Wolff SN; Fay JW; Brown RA; Lynch JP; Bolwell BJ; Stevens DA; Goodman SA; Greer JP; Stein RS; Pineiro LA; Collins RH; Goldsmith LJ; Herzig GP; Herzig RH
Leuk Lymphoma; 1999 Sep; 35(1-2):91-8. PubMed ID: 10512166
[TBL] [Abstract][Full Text] [Related]
36. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
37. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
[TBL] [Abstract][Full Text] [Related]
38. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE
Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111
[TBL] [Abstract][Full Text] [Related]
39. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE
J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593
[TBL] [Abstract][Full Text] [Related]
40. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
